Laura Heathcote

WHAT IS ALREADY KNOWN ON THIS TOPIC HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY Introduction It is estimated that diabetes affects just under half a billion people worldwide, of whom approximately 90% in high-income countries have type 2 diabetes (T2D).1 People with T2D have an elevated risk of developing serious complications such as renal failure, blindness, amputation, cardiovascular disease (CVD), depression, and osteoarthritis.

Methods This analysis was a lifetime horizon, model-based cost-utility analysis using the School for Public Health Research (SPHR) Diabetes Prevention Model v3.2 (hereafter referred to as “the model”),19 20 as prespecified in the PROPELS health economics analysis plan. A model-based analysis was conducted for two reasons.

Keypoints Decision-makers should consider differences in device type, risk group, and access route when considering the health economic evidence on TAVI. Inappropriately combining evidence from different devices, risk groups and access routes may lead to underestimating the economic benefit of TAVI using the most recent generation of devices.